Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Spirit clinical trial focuses on DES safety results

Boston Scientific : 23 May, 2007  (New Product)
Additional data from the Spirit First, II and III clinical trials reaffirms prior safety and and efficacy data for the Taxus Express2 Paclitaxel-Eluting Coronary Stent System and Xience V (Promus) Everolimus Eluting Coronary Stent System.
The Spirit trials focused on the Taxus Express2 Paclitaxel-Eluting Coronary Stent System and Xience V (Promus) Everolimus Eluting Coronary Stent System.

The Promus Stent is a private-labelled Xience V Stent, manufactured by Abbott and distributed by Boston Scientific.

Boston Scientific is the only company to offer the choice of two distinct drug-eluting Stent platforms.

The data were presented by Gregg W Stone, MD, chairman and chief medical officer of the Cardiovascular Research Foundation, Columbia University Medical Center, New York City, at the annual Paris Course on Revascularization (EuroPCR) in Barcelona.

The Spirit First three year clinical follow-up results provided further support for the safety and efficacy of the Xience V (Promus) Stent, with no additional MACE since one year follow up.

In addition, no acute, sub-acute or late Stent thrombosis was seen in either the Xience V (Promus) or BMS control group through three years.

Dr Stone's presentation also included results of a pooled analysis of previously reported Spirit II and III data, where Stent thrombosis rates were shown to be very low for both stents (0.45 percent for the Xience V (Promus) Stent and 0.25 percent for the Taxus Stent, p=0.59).

'It is reassuring to see that both stents performed exceptionally well in the Spirit Clinical Trials on multiple safety measures including Stent thrombosis', said Jeff Goodman, president of International for Boston Scientific.

'The data for these two drug-eluting Stent platforms continue to reinforce Boston Scientific's leadership position in drug-eluting Stent technologies'.

'We also look forward to Abbott presenting and publishing subset data from the Spirit Clinical Trials'.

The Promus Stent has CE Mark approval and is distributed in most European countries and other international markets.

The Xience V (Promus) Everolimus Eluting Coronary Stent System is an investigational device in the USA and not yet approved for sale.

It is currently under FDA review with an anticipated US launch in 2008.

Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo